FastForward Innovations Limited Investee Company Update
19 June 2017 - 4:00PM
RNS Non-Regulatory
TIDMFFWD
FastForward Innovations Limited
19 June 2017
19 June 2017
FastForward Innovations Limited
("FastForward"")
Intensity Therapeutics Issued New Patents
for Technology Platform
-- US Patent 9,636,406 broadens existing claims for the Intensity's proprietary technology
-- Australia intends to grant Intensity patent 2013318338
Intensity Therapeutics, Inc., ("Intensity" or "the Company") in
which FastForward has a holding of 2.118%, is a privately held
biotechnology company developing proprietary cancer immunotherapy
products, and has announced that the United States Patent and
Trademark Office (PTO) has issued the Company patent 9,636,406. In
addition, Intensity noted that the Australian PTO intends to grant
Intensity patent 2013318338.
The Intensity announcement reads as follows:
"Intensity's DfuseRx(SM) platform has identified our lead drug,
INT230-6. This novel product, now in clinical trials, has shown
great promise in regressing tumors and extending life in animal
models of metastatic cancer," said Intensity's President and CEO,
Lewis H. Bender. "The newly issued U.S. patent and soon-to-be
issued Australian patent allow us to protect our unique technology.
The Company now has multiple issued patents and several patent
applications in the U.S. and countries around the world. U.S.
patent 9,636,406 and near-term issuance of Australian patent
2013318338 increases the likelihood that our products can be
secured in important markets."
About INT230-6
INT230-6 is a novel, anti-cancer drug for direct intratumoral
injection. The product contains potent anti-cancer agents that
disperse throughout tumors and diffuse into cancer cells. INT230-6
was identified from Intensity's DfuseRx(SM) platform. In
preclinical studies INT230-6 eradicated tumors by a combination of
direct tumor kill coupled with recruitment of dendritic cells to
the tumor micro-environment that stimulated anti-cancer T-cell
activation. INT230-6 provides complete responder animals with
long-term, durable protection from multiple re-inoculations of the
initial cancer and resistance to other cancers. INT230-6 is being
evaluated in clinical study, IT-01. Further information on the
human trial can be found at www.clinicaltrials.gov
(NCT#03058289).
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a clinical-stage biotechnology
company whose mission is to greatly extend the lives of patients
with cancer. Intensity Therapeutics is pioneering a new
immune-based approach to treat cancer. The Company uses its
DfuseRx(SM) platform technology to create new drug formulations
that disperse throughout a tumor and diffuse into cancer cells.
Drug products created using the technology are capable of
attenuating (killing) a tumor in a manner that allows for the
adaptive immune system to recognize the cancer and attack distal
tumors and micrometastases. Further information can be found at
www.intensitytherapeutics.com.
For further information please visit www.fstfwd.co or
contact:
FastForward Innovations Limited info@fstfwd.co
Josh Epstein/ Ian Burns
------------------------------------------------------------
Beaumont Cornish Limited (Nomad) Tel: +44 (0) 207 628 3396
James Biddle / Michael Cornish
------------------------------------------------------------
Optiva Securities Limited (Broker) Tel: +44 (0) 203 411 1881
Ed McDermott
------------------------------------------------------------
CAUTIONARY STATEMENT
The AIM Market of London Stock Exchange plc does not accept
responsibility for the adequacy or accuracy of this release. No
stock exchange, securities commission or other regulatory authority
has approved or disapproved the information contained herein. All
statements, other than statements of historical fact, in this news
release are forward-looking statements that involve various risks
and uncertainties, including, without limitation, statements
regarding potential values, the future plans and objectives of
FastForward Innovations Ltd. There can be no assurance that such
statements will prove to be accurate, achievable or recognizable in
the near term.
Actual results and future events could differ materially from
those anticipated in such statements. These and all subsequent
written and oral forward-looking statements are based on the
estimates and opinions of management on the dates they are made and
are expressly qualified in their entirety by this notice.
FastForward Innovations assumes no obligation to update
forward-looking statements should circumstances or management's
estimates or opinions change.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKADDPBKDBAD
(END) Dow Jones Newswires
June 19, 2017 02:00 ET (06:00 GMT)
Kuala Innov (LSE:KUL)
Historical Stock Chart
From Apr 2024 to May 2024
Kuala Innov (LSE:KUL)
Historical Stock Chart
From May 2023 to May 2024